Cytek Biosciences, Inc.

Cytek Biosciences Misses on EPS, Stock Up 0.69%

Cytek Biosciences reported a significant miss on EPS, which typically raises concerns about profitability. However, the stock reacted positively, increasing by 0.69%. Investors may be optimistic despite the loss, possibly due to other factors not disclosed in the earnings call.